Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03076918
Other study ID # 2013_23
Secondary ID 2013-A01096-39
Status Terminated
Phase N/A
First received
Last updated
Start date September 2014
Est. completion date February 2017

Study information

Verified date May 2018
Source University Hospital, Lille
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study compares the efficacy and tolerance of a new device (FLEXITHERALIGHT) for photodynamic therapy in the treatment of keratosis actinic in comparison of classical PDT with Aktilite®.


Description:

The study is an intraindividual comparison of two methods. The number of subjects to be enrolled is 47 patients. All participants will receive both two treatments in a single visit : a first period of 2.5 hours of illumination with FLEXITHERALIGHT device followed by a continuous red light Spectrum (between 7 and 10 minutes) with Aktilite® after an appropriate incubation of methyl aminolevulinate).

Patients will complete a pain assessment scale after receiving both treatments, then, 3 follow up visits will be scheduled.


Recruitment information / eligibility

Status Terminated
Enrollment 29
Est. completion date February 2017
Est. primary completion date February 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Clinical diagnosis of minimum 10 previously untreated not pigmented, non-hyperkeratotic AK lesions of Grade I and II of the forehead and/or scalp (according to Olsen et Al. JAAD 1991, cf. REF 31) where other therapies are unacceptable or considered medically less appropriate with a symmetrical repartition on both side of the forehead and/or scalp. The diagnosis of AK will be determined upon clinical evaluation (i.e. visual inspection and palpation) by the investigator.

- Symmetrical areas in terms of number and severity of lesions. The axis of symmetry between the two areas will be defined by the investigator according to the distribution of lesions.

- The two areas to be treated should not be coalescing. A minimum distance of 10mm is required between the lesions located on the 2 symmetrical areas. A minimum distance of 2 mm is required between the lesions on the same side.

- Minimum 5 lesions with similar dimensions at both symmetrical areas will be treated. If the number of lesions is >7, only 7 lesions on each side will be considered.

Exclusion Criteria:

- Patients with porphyria.

- Patients immunosuppressed for idiopathic, disease specific or therapeutic reasons.

- Use of topical corticosteroids to lesional areas within 2 weeks before PDT.

- Patients receiving local treatment (including cryotherapy and curettage, any - Patients receiving topical treatment (including imiquimod, 5-FU and diclofenac, Picato) in face / scalp area within the last 3 months.

- Use of topical retinoids or alpha-hydroxy acids, urea or systemic retinoids, chemotherapy or immunotherapy within 4 weeks of PDT.

- Pigmented AK lesion(s).

- Known allergy to Metvixia, a similar PDT compound or excipients of the cream including arachis oil, or to peanut or soya.

- Participation in other clinical studies either currently or within the last 30 days.

- Female subjects must be of either:

Non-childbearing potential, i.e. post-menopausal or have a confirmed clinical history of sterility (e.g. the subject is without a uterus) or, Childbearing potential, provided there is a confirmed negative urine pregnancy test prior to study treatment, to rule out pregnancy.

- Any condition which may be associated with a risk of poor protocol compliance.

- Patients currently receiving regular ultraviolet radiation therapy

Study Design


Related Conditions & MeSH terms


Intervention

Device:
FLEXITHERALIGHT PDT
Preparation of lesions, MAL application+occlusive dressing during 30 minutes+illumination 2.5 hours
Aktilite® Galderma
Preparation of lesions, MAL application+occlusive dressing during 3 hours+illumination 7 to 10 minutes

Locations

Country Name City State
France CHRU, Hôpital Claude Huriez Lille

Sponsors (3)

Lead Sponsor Collaborator
University Hospital, Lille Institut National de la Santé Et de la Recherche Médicale, France, National Research Agency, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Treated lesion response rate Each treatment area will be counted, graded with Clinical grade of AK, mapped and photographed up to month 6
Secondary Visual Analog scale of pain Measure the pain and local tolerance graduation range 0 to 10 Day 1 and D ay 7.
Secondary Scale for clinical assessment of the subject's skin aspect 4-point scale that ranged of Excellent; No scarring, atrophy or induration, and no or slight occurrence of redness or change in pigmentation compared to adjacent skin. Good: No scarring, atrophy or induration but moderate redness or change in pigmentation compared to adjacent skin, Fair: Slight to moderate occurrence of scarring, atrophy or induration, Poor: Extensive occurrence of scarring, atrophy or induration Months 3 and Months 6
Secondary Fluorescence measure of the PpIX Measures with Fluoderm photometer Baseline, after 3 hours of incubation, in case of treatment interruption, immediately after the treatment, and at 15 and 30 minutes after the end of the treatment.
Secondary Irradiance measure in mW/cm2 for each AK Measures realised with a wattmeter OPHIR LaserSTAR to know the power of light delivered during Aktilite® treatment at Day 1
Secondary Rate of patients with at least 75% of reduction of the lesions The reduction in the number of lesions will be calculated as a function of the initial number:=4 destroyed if 5 lésions; = 5 destroyed if 6 lésions and =6 destroyed if 7 lesions
=4 destroyed if 5 lesions
Months 3 and Months 6
Secondary Dermatology Life Quality Index (DLQI) The questionnaire of 10 questions is completed by the patient to evaluate his quality of life At Day 7, Months 3 and Months 6
Secondary Satisfaction Questionnaire The questionnaire es created by the investigator to evaluate the comfort of the device. Patient will give his overall satisfaction and the will answer 7 questions on a 5-point scale that ranged from Not embarrassing, few embarrassing, embarrassing, Very embarrassing, I Don't know At Day 7, Months 3 and Months 6
See also
  Status Clinical Trial Phase
Completed NCT03076892 - Evaluation of Non-inferiority and Tolerability of the Device PHOS-ISTOS N/A
Completed NCT05356572 - A Pre-market Study to Evaluate the Performance and Safety of a Skin Preparation Device for Removal of Dry Crusty Skin N/A
Recruiting NCT05387525 - A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp Phase 4
Completed NCT02594644 - The Use of Microneedles to Expedite Treatment Time in Photodynamic Therapy N/A
Active, not recruiting NCT02281682 - IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis Phase 4
Completed NCT01458587 - Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK) Phase 2
Completed NCT05260073 - Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis
Active, not recruiting NCT06014697 - OCT and Invasion in Cutaneous Skin Lesions
Completed NCT05279131 - A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis Phase 3
Completed NCT05481073 - UV Sensor in Patients With Actinic Keratosis
Completed NCT03697590 - Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage Phase 4
Withdrawn NCT02813902 - A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors Phase 1
Recruiting NCT05636800 - Microwave Treatment for Actinic Keratosis N/A
Completed NCT02628236 - Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2) Phase 2
Recruiting NCT06135415 - A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis Phase 3
Completed NCT02644187 - Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol N/A
Completed NCT02281136 - MUSE Study of Levulan Kerastick Phase 2
Completed NCT05060237 - Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp Phase 1
Terminated NCT04269395 - A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study Phase 3